Compare Twist Bioscience Corp (TWST) vs Union Pacific Corporation (UNP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Union Pacific Corporation — how do they compare? Twist Bioscience Corp trades at $124.64 (market cap $7.72B), while Union Pacific Corporation trades at $292.17 (market cap $173.99B). The key difference: Union Pacific Corporation is far larger — about 22.5× Twist Bioscience Corp's market cap, and Union Pacific Corporation pays a 1.94% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| TWST | UNP | |
|---|---|---|
Market Cap | $7.72B | $173.99B |
Sector | Health | Industrials |
52-Week High | $124.88 | $307.32 |
52-Week Low | $24.16 | $214.91 |
Enterprise Value | $7.65B | $203.04B |
Dividend Yield | — | 1.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $125.13, up 0.2% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported Q3 2026 revenue of $118.4 million, up 23% year-over-year, beating estimates, but posted a net loss. Revenue growth is strong, yet profitability remains elusive with negative margins. Recent news highlights an upsized $300 million public offering and expanding AI drug discovery pipeline.
Outlook is mixed: robust revenue growth and analyst optimism (78.57% buy ratings) support upside, but persistent losses, cash burn, and high valuation multiples pose significant risks. The stock's proximity to resistance at $126 suggests near-term volatility. Investors should weigh growth potential against financial sustainability concerns.
Union Pacific (UNP) trades at $294.24, up 0.68% with strong fundamentals including 28.85% net margins and 39.7% ROE. The stock shows bullish momentum with Q2 2026 EPS beating estimates by 4.6% and management raising full-year guidance. Technical indicators are neutral overall, with the current price near resistance at $294. Recent news highlights institutional accumulation and a 3% dividend increase announced July 29, 2026.
Outlook remains positive with analyst consensus target of $334.33 (13.6% upside) and 58.7% buy ratings. Key opportunities include service-led growth driving margin expansion, while risks involve high fuel costs and regulatory scrutiny of the Norfolk Southern merger. The company's strong cash flow generation supports continued dividend growth and capital returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
